SCHEMBL4886008

SCHEMBL4886008

O=C(O)c1cc(Cl)ccc1C1CCN(CCN2C(=O)COc3ccccc32)CC1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 9/20 0.71
DRD4 P21917 1/20 0.57
CHRM1 P11229 5/20 0.50
CHRM2 P08172 1/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
DRD2 P14416 1/20 0.50
CHRM3 P20309 1/20 0.50
HTR2A P28223 1/20 0.50
ADRA1A P35348 1/20 0.50
HRH1 P35367 1/20 0.50
ADRA1B P35368 1/20 0.50
KCNH2 Q12809 1/20 0.50
MCHR1 Q99705 1/20 0.50
USP2 O75604 1/20 0.50
KMO O15229 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4437097 0.89 UTS2R (0.67) UTS2RDRD4CHRM1USP2
SCHEMBL4429746 0.89 UTS2R (0.69) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4889112 0.88 UTS2R (0.61) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4428987 0.87 UTS2R (0.73) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4438271 0.86 UTS2R (0.76) UTS2RDRD4CHRM1
SCHEMBL27775670 0.85 UTS2R (0.72) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4440264 0.85 UTS2R (0.74) UTS2RDRD4CHRM1
SCHEMBL4430367 0.84 UTS2R (1.00) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4431346 0.84 UTS2R (0.66) UTS2RDRD4CHRM1CHRM2CHRM4
SCHEMBL4434284 0.83 UTS2R (0.67) UTS2RDRD4CHRM1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US disclosed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 UTS2R 1/4885DRD4 2709/4885CHRM1 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.